Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-06-10

Identification of new antigenic peptides recognized on human tumor cells by cytolytic t lymphocytes

Objectif



Research objectives and content
Several antigens have been identified that are recognized on human tumors by autologous cytolytic T lymphocytes (CTL). Many of these antigens are encoded by MAGE genes that are very selectively expressed by tumor cells. Therefore it is now reasonnable to try to immunize cancer patients against such tumor antigens to induce tumor rejection. Nevertheless, patients would be eligible for such immunotherapy only if their tumor cells express the relevant HLA molecule together with the gene coding for the antigenic peptide.
We intend to find new antigenic peptides encoded by the MAGE genes, in order to allow more patients to benefit from antitumor vaccines containing these antigens. Because some of these MAGE genes code for large proteins, we expect that some peptides corresponding to several regions of these proteins can combine with other HLA molecules to form antigens for anti-tumor CTL. A first strategy consists in searching the protein sequences for peptides containing HLA binding motifs, testing their binding in vitro to the relevant HLA molecule, and using the best candidates to stimulate T lymphocytes. An alternative method is to transfect dendritic cells or to load them with recombinant protein, and use these modified dendritic cells to induce primary antigen-specific CTL response in vitro. Advantages of this strategy include the covering of a complete protein with fewer experiments, and a more physiologic selection of the CTL epitopes by the antigen-presenting cells themselves. Training content (objective, benefit and expected impact)
The first objective of this training is learning techniques in molecular and cellular immunology in order to be able to identify potential tumor specific antigens. The Cellular Genetics Unit of the ICP have pioneered these techniques in the past and seems to me a very good place for postdoctoral training in tumor immunology. The development of efficient in vitro-priming protocols would be a new tool for many tumor models, and I will then be able to apply these techniques in other institutions. The possibility for me to pursue my postdoctoral position in the Cellular Genetics Unit will let me time enough to bring this project to issue and finally will offer me the best chances to get a position in a research institution like INSERM on my return to France.
Links with industry / industrial relevance (22)
Recombinant proteins for several tumor antigens such as MAGE-3 will be used for in vitro loading of antigen-presenting cells. This recombinant protein will be produced within one year by the Smith Kline Corporation phamarceutical company. This protein will also be available for clinical trials organized in several european clinical centers.

Champ scientifique (EuroSciVoc)

CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN. Voir: Le vocabulaire scientifique européen.

Vous devez vous identifier ou vous inscrire pour utiliser cette fonction

Programme(s)

Programmes de financement pluriannuels qui définissent les priorités de l’UE en matière de recherche et d’innovation.

Thème(s)

Les appels à propositions sont divisés en thèmes. Un thème définit un sujet ou un domaine spécifique dans le cadre duquel les candidats peuvent soumettre des propositions. La description d’un thème comprend sa portée spécifique et l’impact attendu du projet financé.

Appel à propositions

Procédure par laquelle les candidats sont invités à soumettre des propositions de projet en vue de bénéficier d’un financement de l’UE.

Données non disponibles

Régime de financement

Régime de financement (ou «type d’action») à l’intérieur d’un programme présentant des caractéristiques communes. Le régime de financement précise le champ d’application de ce qui est financé, le taux de remboursement, les critères d’évaluation spécifiques pour bénéficier du financement et les formes simplifiées de couverture des coûts, telles que les montants forfaitaires.

RGI - Research grants (individual fellowships)

Coordinateur

CHRISTIAN DE DUVE INSTITUTE OF CELLULAR PATHOLOGY
Contribution de l’UE
Aucune donnée
Adresse
Avenue Hippocrate 74
1200 BRUXELLES
Belgique

Voir sur la carte

Coût total

Les coûts totaux encourus par l’organisation concernée pour participer au projet, y compris les coûts directs et indirects. Ce montant est un sous-ensemble du budget global du projet.

Aucune donnée

Participants (1)

Mon livret 0 0